EpiVax and Massachusetts General Hospital Advance on T cell-Targeted Epitope Vaccine for Q Fever
EpiVax and MGH release exciting new data on a T cell driven vaccine candidate for Q Fever.
- EpiVax and MGH release exciting new data on a T cell driven vaccine candidate for Q Fever.
- Q Fever is a zoonotic disease caused by Coxiella burnetii bacterial infection.
- Researchers aim to work closely with regulatory agencies to develop a preclinical testing plan suitable for a T cell-driven vaccine candidate.
- EpiVax is a biotechnology company with expertise in T cell epitope prediction, immune modulation, and rapid vaccine design.